BR9912609A - Methods of using a somatostatin analog - Google Patents

Methods of using a somatostatin analog

Info

Publication number
BR9912609A
BR9912609A BR9912609-5A BR9912609A BR9912609A BR 9912609 A BR9912609 A BR 9912609A BR 9912609 A BR9912609 A BR 9912609A BR 9912609 A BR9912609 A BR 9912609A
Authority
BR
Brazil
Prior art keywords
conditions
diseases
cancer
methods
somatostatin analog
Prior art date
Application number
BR9912609-5A
Other languages
Portuguese (pt)
Inventor
Jacques-Pierre Moreau
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of BR9912609A publication Critical patent/BR9912609A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"MéTODOS DE USO DE UM ANáLOGO DE SOMATOSTATINA"<D>. A presente invenção refere-se a um método de tratamento de uma ou mais das doenças e/ou condições que seguem, que compreendem administrar a um paciente com necessidade o composto H-g(b)-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH~ 2~, onde as Cisteínas estão ligadas através de uma ligação dissulfeto, ou um sal farmaceuticamente aceitável dele, com mais preferência o sal de acetato do composto, no tratamento de certas doenças e/ou condições tal como condições e/ou doenças gastroenterológicas, doenças e/ou condições endocrinológicas, vários tipos de câncer e condições associadas ao câncer tal como caquexia de câncer e no tratamento de hipotensão e ataques de pânico.Invention Patent: <B> "METHODS OF USE OF A SOMATOSTATIN ANALOG" <D>. The present invention relates to a method of treating one or more of the diseases and / or conditions that follow, which comprise administering to a patient in need the compound Hg (b) -D-Nal-Cys-Tyr-D-Trp -Lys-Val-Cys-Thr-NH ~ 2 ~, where the Cysteines are linked via a disulfide bond, or a pharmaceutically acceptable salt thereof, more preferably the acetate salt of the compound, in the treatment of certain diseases and / or conditions such as gastroenterological conditions and / or diseases, endocrinological diseases and / or conditions, various types of cancer and conditions associated with cancer such as cancer cachexia and in the treatment of hypotension and panic attacks.

BR9912609-5A 1998-07-30 1999-07-29 Methods of using a somatostatin analog BR9912609A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9469398P 1998-07-30 1998-07-30
US12652598A 1998-07-30 1998-07-30
PCT/US1999/017294 WO2000006185A2 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue

Publications (1)

Publication Number Publication Date
BR9912609A true BR9912609A (en) 2001-05-02

Family

ID=26789150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912609-5A BR9912609A (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analog

Country Status (16)

Country Link
EP (1) EP1100532A2 (en)
JP (1) JP2002521456A (en)
KR (1) KR20010071071A (en)
CN (1) CN1334742A (en)
AR (1) AR023633A1 (en)
AU (2) AU770193B2 (en)
BR (1) BR9912609A (en)
CA (1) CA2335654A1 (en)
CZ (1) CZ2001157A3 (en)
HU (1) HUP0102839A3 (en)
IL (2) IL140837A0 (en)
MX (1) MXPA01000969A (en)
NO (1) NO324123B1 (en)
NZ (1) NZ509348A (en)
PL (1) PL346361A1 (en)
WO (1) WO2000006185A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2002009739A1 (en) * 2000-07-27 2002-02-07 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
DE60236225D1 (en) 2001-03-06 2010-06-10 Univ Tulane Method for modulating the proliferation of thyroid cancer cells
GB0109461D0 (en) * 2001-04-18 2001-06-06 Univ London New Gene
WO2003061592A2 (en) 2002-01-22 2003-07-31 New York University Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
EP3473643A1 (en) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatemnt of cancer
JP5728380B2 (en) 2008-06-12 2015-06-03 シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ Suppression of neuroendocrine disease
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN101935252B (en) * 2010-07-29 2013-01-30 广东省农业科学院科技情报研究所 Landscape plant growth retardant and preparation method thereof
CA2869442C (en) * 2012-04-12 2020-09-08 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
CN105168115A (en) * 2015-09-02 2015-12-23 中国药科大学 Oral medication path of somatostatin analogue polypeptide drug
WO2017212390A1 (en) * 2016-06-06 2017-12-14 Emcure Pharmaceuticals Ltd, Process for lanreotide acetate preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ATE140237T1 (en) * 1989-12-08 1996-07-15 Univ Tulane OCTAPEPTIDE ANALOGUES OF SOMATOSTATIN WITH THREONINE IN POSITION 6
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
ATE262921T1 (en) * 1997-05-13 2004-04-15 Sod Conseils Rech Applic SOMATOSTATIN AND SOMATOSTATIN AGONITS FOR THE TREATMENT OF INSULIN SENSITIVITY AND SYNDROMES X

Also Published As

Publication number Publication date
IL140837A0 (en) 2002-02-10
AU770193B2 (en) 2004-02-12
CN1334742A (en) 2002-02-06
AR023633A1 (en) 2002-09-04
PL346361A1 (en) 2002-02-11
EP1100532A2 (en) 2001-05-23
JP2002521456A (en) 2002-07-16
AU2004201783A1 (en) 2004-05-27
WO2000006185A3 (en) 2000-08-03
NZ509348A (en) 2004-02-27
CA2335654A1 (en) 2000-02-10
NO20010481D0 (en) 2001-01-29
HUP0102839A2 (en) 2002-01-28
AU5244799A (en) 2000-02-21
NO20010481L (en) 2001-03-21
NO324123B1 (en) 2007-08-27
CZ2001157A3 (en) 2002-02-13
KR20010071071A (en) 2001-07-28
WO2000006185A2 (en) 2000-02-10
IL181349A0 (en) 2007-07-04
HUP0102839A3 (en) 2002-02-28
MXPA01000969A (en) 2003-04-07

Similar Documents

Publication Publication Date Title
BR9912609A (en) Methods of using a somatostatin analog
EP1201241A3 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
BR9812484A (en) Combination therapy for the eradication of detectable hcv-rna in patients with chronic hepatitis c infection
WO2005072505A3 (en) Methods and compositions for the treatment of skin changes associated with aging and environmental damage
NO20003051L (en) Method of administration of AspB28 human insulin
BR0009776A (en) Treatment method
ATE227717T1 (en) 3-PYRIDYLENE ANTIOMERS AND THEIR USE AS ANALGESICS
ATE496048T1 (en) PHENYLCARBOXAMIDE COMPOUNDS FOR PAIN TREATMENT
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
MXPA04003773A (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment.
MX2008001520A (en) Tizanidine compositions and methods of treatment using the compositions.
PT998287E (en) USES OF LEVOBUPIVACAINE
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
BR0212249A (en) Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, and use of a compound
ATE344664T1 (en) IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI
HUP9903679A2 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
DE60141759D1 (en) METHOD OF TREATING THE CENTRAL NERVOUS SYSTEM BY APPLICATION OF STRUCTURAL ANALOGUES OF IGF
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
PT1032402E (en) USE OF CITICOLIN FOR THE TREATMENT OF MULTIPLE SCLEROSIS
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.